Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CD19 CART and application thereof

A use and cell technology, applied in the field of lentiviral vectors, can solve the problems of severe immune and inflammatory reactions, and achieve the effect of reducing CART reactivity, avoiding serious adverse reactions, and effective and safe cancer treatment functions.

Inactive Publication Date: 2018-01-19
SHENZHEN PREGENE BIOPHARMA CO LTD
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The present invention aims to solve the problem of CD19 CART killing tumor cells in blood vessels and bone marrow while causing severe immune and inflammatory responses, leading to cytokine release syndrome in patients, and reducing or relieving hyperthermia, hypotension, hypoxia, hyperthermia, Symptoms or phenomena such as organ dysfunction and neurotoxicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD19 CART and application thereof
  • CD19 CART and application thereof
  • CD19 CART and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0029] The present invention aims at various problems in the CD19 CART of 3 foreign companies, designs a brand-new chimeric antigen receptor gene, adopts mouse FMC63 clone (without patent protection) in the CD19 single-chain antibody recognition aspect, in the CD19 The combination of the hinge region and the transmembrane region adopts a different structure from that of foreign companies, and uses all the cytoplasmic region fragments of the 4-1BB molecule and the CD3ζ molecule in the cytoplasmic region. The difference between the present invention and the CD19 CAR structure of foreign companies can be found in figure 1 . The specific idea is as follows:

[0030] (1) Use FMC63 single-chain antibody to ensure the specificity and affinity of CD19 recognition;

[0031] (2) The hinge region was lengthened (compared with the other 3 companies, at least 49 amino acids were added) to reduce the reactivity of CART cells ( figure 1 , Figure 8 , the killing efficiency is appropriately...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a CD19 CART for treating tumor and further relates to a lentiviral vector, a CD19 CAR T2A EGFRt gene and application of the lentiviral vector and the CD19 CAR T2A EGFRt gene. According to the CD19 CART, under the premise that the CART killing effect is not affected, the reactivity is properly reduced, the reaction is terminated timely when serious adverse reaction is causedby CART, and thus the treating effect and safety are both taken into consideration.

Description

technical field [0001] The present invention belongs to the field of immune cell therapy, and in particular relates to a CD19 CART for treating tumors, a lentiviral vector, a CD19 CAR T2A EGFRt gene, and applications thereof. Background technique [0002] Chimeric Antigen Receptor modified T cells (CART) express an artificially synthesized CAR molecule (Chimeric Antigen Receptor) on the T cell membrane through genetic modification, allowing T cells to bind with antigens and antibodies. way to recognize and kill tumor cells. The CAR molecule includes an extracellular binding region (a single-chain antibody (scFv) derived from a monoclonal antibody that can specifically recognize a target antigen), a hinge region, a transmembrane region, and an intracellular signal segment. This technology has several advantages. For example, CAR protein recognizes TAA (tumor associated antigen, tumorassociated antigen) on the tumor surface in an MHC (major histocompatibility complex)-indepen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/62C12N15/867C12N5/10A61K35/17A61P35/02A61P35/00
Inventor 张继帅栗红建赵杨杨余祥郑孟韬张健苏红昌何鹏华彭华姜冬冬何昱
Owner SHENZHEN PREGENE BIOPHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com